The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
732
CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)
Percentage of subjects in each treatment group achieving "success" at Week 12, with "success" defined as an IGA score of "clear (score=0)" or "almost clear (score=1)" and at least a two-point reduction in IGA compared to Baseline.
Time frame: Week 12
Change From Baseline in Non-inflammatory Lesion (NIL) Counts
Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.
Time frame: Baseline and Week 12
Change From Baseline in Inflammatory Lesion (IL) Counts
Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.
Time frame: Baseline and Week 12
Change From Baseline in Total Lesion Counts
Absolute change from Baseline in total lesions counts in each treatment group at Week 12.
Time frame: Baseline and Week 12
Percent Change From Baseline in Total Lesion Counts
Percent change from Baseline in total lesions counts in each treatment group at Week 12.
Time frame: Baseline and Week 12
Percent Change From Baseline in Non-inflammatory Lesion Counts
Percent change from Baseline in non-inflammatory lesions count in each treatment group at Week 12.
Time frame: Baseline and Week 12
Percent Change From Baseline in Inflammatory Lesion Counts
Percent change from Baseline in inflammatory lesions count in each treatment group at Week 12.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clear dermatology & Aesthetic Center
Scottsdale, Arizona, United States
Johnson Dermatology
Fort Smith, Arkansas, United States
Center for Dermatology and Laser Surgery
Sacramento, California, United States
Belleair Research Center
Pinellas Park, Florida, United States
Arlington Dermatology
Arlington Heights, Illinois, United States
Kansas City Dermatology, PA
Overland Park, Kansas, United States
Maryland Laser Skin and Vein Institute
Hunt Valley, Maryland, United States
Sadick Research Group, LLC
New York, New York, United States
Skin Specialty Dermatology
New York, New York, United States
Clinical Partners, LLC
Johnston, Rhode Island, United States
...and 42 more locations
Time frame: Baseline and Week 12